Select your country
Select a country to go to the website of the respective STADA sales company.
Saudi Arabia (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (4)
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022
- Investor News
- Press Release
Bad Vilbel, June 8, 2018 – STADA Arzneimittel AG (“STADA”) has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022 (ISIN: XS1213831362, WKN: A14KJP, Common Code: 121383136) (the “STADA 2015 Notes”), to vote without a physical meeting with the object of appointing a common representative and making related mechanical amendments to the conditions of the STADA 2015 Notes (the “Consent Solicitation”).
This modification to the STADA 2015 Notes is being arranged by STADA in connection with the provision of credit support by STADA and certain of its subsidiaries under the 2017 financing provided to its majority shareholder, Nidda Healthcare GmbH (the “Security”). The appointment of the common representative of the STADA 2015 Notes is designed to procure the extension of the Security to the holders of the STADA 2015 Notes on an equal and rateable basis with Nidda Healthcare GmbH’s creditors under the 2017 financing. Accordingly, holders of the STADA 2015 Notes are encouraged to attend the noteholder meeting set out in the Consent Solicitation.
STADA also intends to offer to acquire STADA 2015 Notes at par plus accrued interest (to the date of acquisition) giving those holders who do not wish to participate in the proposed consents the ability to sell their STADA 2015 Notes. Details and conditions of the related tender offer for cash will be announced separately and nearer the time for the vote in respect of the Consent Solicitation.
STADA Arzneimittel AG / Corporate Treasury / Frank Seiler / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-4476 / Fax: +49 (0) 6101 603-3721 / E-mail: firstname.lastname@example.org